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Immunophenotyping by flow cytometry and frozen-section immunoperoxidase was compared on 21 consec-
utive lymph node biopsy specimens, of which a diagnosis of lymphoma was made for 11 specimens. Samples
for flow cytometry were obtained by a fine-needle aspiration technique. Concordance between frozen-section
immunoperoxidase and flow cytometry for all routine markers on all specimens ranged from 76 to 100%. In
general, B-cell markers showed poorer concordance than T-cell markers, with K and A light chains having the
poorest concordance, at 76% each. Flow cytometry was significantly more sensitive (90 versus 30%Yo; P < 0.006)
and had a significantly higher negative predictive value (100 versus 63%; P < 0.006) than frozen-section
immunoperoxidase for demonstrating light-chain restriction. There was no significant difference in the
specificities (100 versus 91%) or positive predictive values (100%v each) between the two methods. Both methods
demonstrated characteristic immunophenotypes for intermediate cell lymphomas, small lymphocytic lympho-
mas, and T-cell lymphoblastic lymphomas. Frozen-section immunoperoxidase and flow cytometry appear to be
significantly concordant methods for immunophenotypic analysis of lymph node biopsies. Light-chain
restriction is more readily demonstrated by flow cytometry than frozen-section immunoperoxidase. We believe
that ex vivo fine-needle aspiration is a simple and reliable method of obtaining cell suspensions of lymph nodes
for flow cytometry.
The advent of immunophenotyping of samples from patients
with lymphoproliferative disorders has added much to the
classification and understanding of these processes. It is now
recognized that the majority of normal lymphoid subsets and
developmental stages are also represented in clonal lympho-
proliferative disorders (8, 10, 33). Immunophenotyping also
has practical diagnostic utility in supporting the diagnosis of
malignancy by demonstrating clonality (15, 18, 28, 32). Clonal-
ity for B-cell processes is demonstrated by evidence of mono-
typic light-chain expression or light-chain restriction (11, 21,
22). Since committed B cells produce a single immunoglobulin
light chain, monoclonal populations display a single immuno-
globulin light chain, K or X, on the surfaces of all of their cells.
Polyclonal populations are made up of a mixture of cells that
produce either light chain. Therefore, they do not demonstrate
light-chain restriction. For T-cell processes, monoclonality is
supported by demonstration of an aberrant immunophenotype
for the majority of cells. For an immunophenotyping method
to be useful as an aid in the classification and diagnosis of
lymphomas and lymphoid leukemia, it should be able to
demonstrate light-chain restriction in monoclonal B-cell pro-
cesses and its absence in polyclonal B-cell processes, demon-
strate aberrant immunophenotypes in T-cell processes, and
demonstrate characteristic immunophenotypes.
Several methods exist for immunophenotyping lymphomas
in lymph node biopsies, including immunoperoxidase on fixed
paraffin-embedded tissue (18-20), immunoperoxidase on fresh
frozen tissue (frozen-section immunoperoxidase [FSIP]) (3, 30,
31), immunofluorescence on fresh frozen tissue (34), immuno-
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peroxidase or immunofluorescence on cytospin preparations
(26), or flow cytometry (FCM) on cell suspensions (2, 5, 6, 12,
16). Each of these methods has unique advantages and disad-
vantages. Immunoperoxidase on formalin-fixed, paraffin-em-
bedded tissue provides the best morphology for correlation
with staining. However, this is limited by poor antigen preser-
vation and difficulties in demonstrating antigens restricted to
cell surfaces, which include the majority of lymphoid markers.
Sufficient antibodies have been developed for the separation of
B- and T-cell processes on formalin-fixed, paraffin-embedded
tissue, but immunoglobulin light chains are not reliably dem-
onstrated on cell surfaces by this method (18-20, 25). FSIP
allows demonstration of most surface markers and some
morphology for correlation with staining, but FSIP may also
have difficulty reliably demonstrating immunoglobulin light
chains on cell surfaces (24, 25, 28, 29, 31, 34). This common
limitation of these immunophenotyping techniques likely re-
sults from the high level of background staining of ubiquitous
immunoglobulins in extracellular fluids and connective tissues
and variable immunoglobulin expression by lymphomas. This
might be compounded by the reduced cell surface area in
tissue sections. Immunofluorescence on frozen tissue has suf-
ficiently strong positive staining with a sufficiently low back-
ground for demonstration of immunoglobulin light chains on
cell surfaces, but it provides only general architectural mor-
phologic correlation, requires a fluorescence microscope, and
does not provide permanent material for future review (25,
34). FCM has proven to be extremely useful for immunophe-
notyping leukemia, providing statistical power, sensitivity, and
automation (3, 6, 9). Because of these benefits, FCM is now
more widely used for immunophenotyping lymphomas as well.
The major disadvantages of FCM for immunophenotyping
node-based lymphomas are limited morphologic correlation,
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potential sampling error, and the need to prepare viable cell
suspensions (13, 16).
We undertook a comparative immunophenotyping study of
two of these methods, FSIP and FCM, on consecutive lymph
node biopsies to determine the concordance of FSIP and FCM
for routine markers, assess the diagnostic performance of each
method for demonstrating light-chain restriction, assess the
ability of each method to demonstrate characteristic immuno-
phenotypes, and determine the utility of ex vivo fine-needle
aspiration (FNA) for obtaining cell suspensions for FCM.
MATERIALS AND METHODS
Sample collection. Samples for both FCM and FSIP con-
sisted of all lymph nodes submitted to the University of North
Carolina Hospitals Surgical Pathology Laboratory for lym-
phoma workup from November 1991 to March 1992. Samples
for FCM were collected by an ex vivo FNA technique by using
a 10-ml syringe holder (gun) and a 22-gauge needle (1, 7).
Multiple passes of each lymph node were made, sampling all
areas. The aspirated material was flushed into RPMI tissue
culture medium (Lineberger Comprehensive Cancer Center
Tissue Culture Facility, University of North Carolina-Chapel
Hill) to obtain disaggregated cell suspensions. Simultaneous
air-dried, Diff-Quik (Baxter Scientific Products, Charlotte,
N.C.)-stained smears were prepared to verify the collection of
representative samples and to aid in diagnosis. The viabilities
of the cell suspensions were assessed with trypan blue, yielding
sample viabilities of 80% ± 14%. A representative portion of
each lymph node specimen was soaked in phosphate-buffered
saline (PBS; pH 7.2 to 7.4) for 20 min, covered with Tissue-Tek
OCT tissue embedding medium (Baxter), and snap-frozen in
liquid nitrogen for FSIP. Human palatine tonsils for lymphoid
tissue controls were processed in the same manner.
Monoclonal antibodies. Samples from all lymph nodes were
labeled for FCM and FSIP analysis with antibodies directed to
a core set of lymphoid antigens (CD3, CD4, CD8, CD20,
CD45, K light chain, and K light chain). All samples for FCM
were also labeled with antibodies to CD2, CD5, CD7, CD10,
CD19, CD25, CD38, and HLA-DR. Samples from selected
lymph nodes were labeled for FSIP with antibodies to CD2,
CD5, CD7, CD19, and CD22. Commercial antibodies for FSIP
were obtained from Dako Corporation, Carpintina, Calif., and
ICN, Irvine, Calif. Commercial fluorochrome (fluorescein iso-
thiocyanate and phycoerythrin)-conjugated monoclonal anti-
bodies were obtained from Becton Dickinson Immunocytom-
etry Systems, San Jose, Calif., and GenTrak, Inc., Plymouth
Meeting, Pa.
FCM. Aliquots of the cell suspensions were added to
staining tubes containing the appropriate fluorochrome-conju-
gated monoclonal antibodies. Following incubation at 4°C for
15 min, the samples were centrifuged, washed with PBS
containing bovine serum albumin and sodium azide, and
resuspended in 0.5 ml of 1% paraformaldehyde in PBS. The
labeled specimens were then run on a FACScan flow cytome-
ter with an argon ion laser emitting at 498 nm (Becton
Dickinson Immunocytometry Systems). Two-color analysis was
performed by using Consort 30, SIMULSET, and LYSYS
analysis software (Becton Dickinson Immunocytometry Sys-
tems), yielding a percentage of total cells positive for each
antigen. Gates were set by light-scatter characteristics and
were verified by staining for CD45 and CD14. Light-chain
results were considered indeterminate when >75% of the
CD19-positive cells stained for both light chains.
FSIP. Frozen sections of the lymph nodes and control tonsils
of 4 ,um were cut onto silanized slides (ProbeOn Plus; Fisher
Scientific, Pittsburgh, Pa.), labeled with the appropriate anti-
bodies, and developed by the ABC method (Vectastain Elite
kit; Vector Laboratories, Inc., Burlingame, Calif.) with DAB
chromogen (Biomeda Corp., Foster City, Calif.) by using a
capillary gap apparatus (Microprobe; Fisher Scientific). Spe-
cific details of the staining procedure were described previ-
ously (4). Sections of lymph nodes were paired against sections
of control tissue. The staining was graded for each antigen by
light microscopy into five categories, each reflecting a range of
percentage of total cells that were positive, as follows: negative,
<10%; 1+, 10 to 25%; 2+, 26 to 50%; 3+, 51 to 75%; and 4+,
>75%. Results for light chains were considered indeterminate
when staining was 4+ with both markers.
Statistical analysis. The concordance of immunostaining
between the two methods, defined as FSIP within ±41 corre-
sponding grade of FCM, was determined for each marker in
each lymph node specimen. A concordance percentage [(num-
ber concordant/total) x 1001 was then determined for each
marker for all lymph nodes and the subgroups of samples
representing B-cell lymphomas, benign lymphadenopathies,
and Hodgkin's disease. The 95% confidence intervals for
concordance percentages were obtained from a binomial dis-
tribution chart (23), and the observed values were compared
with 0.5 (50%) by using binomial probability tables (17).
Demonstration of light-chain restriction (LCR) was deter-
mined for each method according to the following definitions:
LCR K/A < 0.25 or K/K > 7.5. This definition was translated
into categories of grading with ratios of corresponding percent-
ages that met or exceeded the definition, as follows: for FSIP,
LCR- K = 4+, A = negative (K/A > 7.5); KA 2+, K =
negative; or K = 4+, K = 1+ (K/K < 0.25). The sensitivity,
specificity, positive predictive value, and negative predictive
value for demonstrating LCR were then calculated for each
method. For the purposes of these calculations, the "gold
standard" LCR was defined as present in B-cell lymphomas
and absent from all other samples. B-cell lymphomas were
defined by the combination of a light microscopy diagnosis of
lymphoma and the presence of surface immunoglobulin on
tumor cells. This approach is based on current understanding
of B-cell lymphomas, specifically, that those tumors that ex-
press light chains do so in a monotypic or restricted fashion
and other lymphoid processes do not (11, 21, 22). The 95%
confidence intervals for these diagnostic performance statistics
were obtained as discussed above for concordance percent-
ages, and those of each method were compared by using a
normal approximation to the distribution of the difference of
two binomial proportions (17).
RESULTS
Concordance of FCM and FSIP. Twenty-one lymph node
biopsy specimens were analyzed by FSIP and FCM (Table 1).
The final diagnoses included the following: 10 B-cell lympho-
mas, 1 T-cell lymphoma, 3 cases of Hodgkin's disease, and 7
benign lymphadenopathies.
The concordance of the two methods was determined for
each marker. Concordance for all markers in all cases ranged
from 76 to 100% (Table 2). These proportions were signifi-
cantly greater than 50% for all commonly determined markers
(all markers, excluding CD2, CD5, and CD7, determined by
both methods; P < 0.0001 to 0.0207). In general, the T-cell
markers showed greater concordance than the B-cell markers,
with K and K light chains having the lowest concordance (76%).
Similar concordances were found in the subgroups of B-cell
lymphomas, Hodgkin's disease, and benign lymphadenopa-
thies.
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TABLE 1. Immunophenotyping results by samplea
CD3 CD4 CD5 CD7 CD8 CDIO, CD19 CD20 K A K/X,Sample Diagnosis-F M FCMFCM" FSIP' FCM FSIP FCM FSIP FCM FSIP FCM FSIP M FCM FSIP FCM FSIP FCM FSIP FCM FSIP
1 ICL 18 2+ 9 Neg 98 4+ 16 ND 7 Neg 3 81 ND 59 3+ 4 Neg 84 Neg 0.03
2 ICL 23 1+ 18 1+ 31 1+ 8 ND 3 Neg 0 83 ND 87 3+ 82 2+ 1 1+ 82
3 ICL 36 1+ 8 1+ 37 1+ 8 ND 5 Neg 1 55 4+ 84 3+ 58 4+ 4 1+ 27
4 ICL 23 1+ 10 1+ 93 4+ 17 ND 12 1+ 0 75 4+ 80 Neg 2 Neg 77 4+ 0.01
5 SLL 5 1+ 3 Neg 92 4+ 2 ND 1 Neg 0 90 ND 4 Neg 86 1+ 1 Neg 86
6 SNCNB 2 1+ 3 Neg 0 2+ 1 ND 3 1+ 1 47 ND 93 3+ 1 Neg 88 Neg 0.01
7 SNCNB 5 1+ 2 Neg 5 ND 3 ND 5 1+ 37 39 ND 54 4+ 1 Neg 34 3+ 0.03
8 FML 35 2+ 36 2+ 42 2+ 24 ND 8 Neg 59 58 ND 83 4+ 3 4+ 47 4+ 0.06
9 FML 35 2+ 29 1+ 30 ND 18 ND 4 Neg 57 68 ND 81 3+ 66 2+ 67 Neg 0.99
10 FSCL 50 2+ 43 2+ 50 ND 37 ND 4 Neg 3 37 ND 74 1+ 3 Neg 50 3+ 0.06
11 TLBL 16 4+ 88 4+ 93 4+ 7 Neg 3 Neg 1 3 ND 32 1+ 2 Neg 3 Neg 0.67
12 MC HD 31 3+ 14 2+ 30 ND 28 ND 20 2+ 0 48 2+ 58 1+ 37 1+ 30 1+ 1.2
13 NS HD 45 2+ 26 1+ 47 ND 43 ND 21 1+ 0 50 1+ 57 1+ 26 1+ 25 Neg 1
14 LD HD 72 3+ 54 3+ 70 ND 61 ND 17 1+ 1 16 1+ 30 1+ 23 Neg 15 Neg 1.5
15 Granulomas 77 4+ 49 2+ 66 ND 50 ND 13 2+ 0 14 1+ 16 1+ 8 Neg 5 Neg 1.6
16 Sarcoid 32 3+ 21 3+ 28 ND 25 ND 7 1+ 3 62 2+ 63 2+ 38 1 + 29 1 + 1.3
17 DLA 83 3+ 52 2+ 84 ND 76 ND 29 1+ 0 15 2+ 18 2+ 8 1+ 5 1+ 1.6
18 Histiocytosis 77 4+ 61 4+ 71 ND 70 ND 12 1+ 0 19 1+ 20 1+ 64 Neg 23 Neg 2.8
19 BLH 69 3+ 46 2+ 73 ND 64 ND 24 1+ 1 27 ND 27 1+ 14 Neg 13 Neg 1
20 BLH 45 3+ 38 3+ 46 ND 36 ND 6 1+ 1 43 2+ 45 2+ 22 Ind 17 Ind 1.3
21 BLH 49 4+ 31 3+ 54 ND 41 ND 18 3+ 4 46 1+ 47 1+ 34 1+ 16 1+ 2.1
" ICL, intermediate cell lymphoma; SLL, small lymphocytic lymphoma; SNCNB, small noncleaved non-Burkitt's lymphoma; FML, follicular mixed lymphoma; FSCL,
follicular small cleaved lymphoma; TLBL, T-cell lymphoblastic lymphoma; MC HD, mixed cellularity Hodgkin's disease; NS HD, nodular sclerosis Hodgkin's disease;
LD HD, lymphocyte depleted Hodgkin's disease; DLA, dermatopathic lymphadenopathy; BLH, benign lymphoid hyperplasia; FCM, flow cytometry; FSIP,
immunoperoxidase; ND, not determined.
b Values are percent positive cells.
'Grade corresponding to percent positive cells (neg, negative = <10%; 1+, 10 to 25%; 2+, 26 to 50%; 3+, 51 to 75%; 4+, >75%; Ind, indeterminate).
Demonstration of LCR. FCM was significantly more sensi-
tive (90 versus 30%; P = 0.006) and had a significantly higher
negative predictive value (100 versus 63%; P < 0.006) than
FSIP for demonstrating LCR. There was no significant differ-
ence in the specificities (100 versus 91%; P > 0.3) or positive
predictive values (100% each; P > 0.9) between the two
methods (Table 3). FCM yielded indeterminate results in one
follicular mixed lymphoma (sample 9; Table 1). FSIP yielded
indeterminate results in one follicular mixed lymphoma (sam-
ple 8; Table 1) and one benign sample (sample 20; Table 1).
Demonstration of characteristic immunophenotypes. The
T-cell lymphoblastic lymphoma (sample 11; Table 1) had an
aberrant immunophenotype (strong CD2 and CD5 expression
but low CD7 expression) by both FCM and FSIP, although the
methods were discordant with respect to CD3 (16% by FCM;
4+ surface staining by FSIP). The four intermediate cell
lymphomas and one small lymphocytic lymphoma (samples 1
to 5; Table 1) showed expression of CD19 or CD20 and CD5
by both FCM and FSIP. Coexpression of these markers by
individual cells was demonstrated by dual staining with FCM.
The two follicular mixed lymphomas (samples 8 and 9; Table
1) showed CD10 expression by FCM.
DISCUSSION
Although FCM and FSIP are both widely used for immuno-
phenotyping of lymphomas, both have been evaluated on large
numbers of samples, and both have shown advantages over
other methods, little has been published regarding the com-
parative performance of each method. The present study was
performed to directly compare immunophenotyping by FCM
and FSIP. By the frequency of utilization of each method, one
TABLE 2. Concordance for markers by FCM and FSIP
All samples B-cell lymphomas Benign samples Hodgkin's disease
Marker
% Concordance' No. % Concordance No. % Concordance No. % Concordance No.
CD2 100 (lb) 2 100 (I) 1 NDC (ND) 0 ND 0
CD3 95 (76-100) 21 100 (69-100) 10 86 (41-100) 7 100 3
CD4 95 (76-100) 21 100 (69-100) 10 86 (41-100) 7 100 3
CD5 88 (48-100) 8 86 (41-100) 7 ND (ND) 0 ND 0
CD7 100 (I) 1 ND (ND) 0 ND (ND) 0 ND 0
CD8 95 (76-100) 21 100 (69-100) 10 86 (41-100) 7 100 3
CD19 100 (71-100) 11 ND (ND) 0 100 (57-100) 7 33 3
CD20 81 (58-94) 21 80 (44-98) 10 100 (57-100) 7 100 3
CD45 100(84-100) 21 100 (69-100) 10 100 (57-100) 7 100 3
K 76 (55-92) 21 70 (35-95) 10 71 (27-96) 7 100 3
A 76 (55-92) 21 60 (26-90) 10 86 (41-100) 7 100 3
Values are percent observed concordance (95% confidence interval).
"I, insufficient sample size.
ND, not determined.
VOL. 1, 1994
302 BIESEMIER ET AL.
TABLE 3. Demonstration of LCR by FCM and FSIPa
Method % Sensitivity' % Specificity % pV+b % pv_C
FCM 90 (56-100) 100 (71-100) 100 (66-100) 100 (71-100)
FSIP 30 (7-65) 91 (58-100) 100 63 (35-87)
a Observed value (95% confidence interval).
b PV+, positive predictive value.
c PV-, negative predictive value.
would expect each to perform reasonably well with most
markers, and therefore that the two methods would give
similar results for the same markers on the same samples (high
concordance). Reasonable concordances were found in the
present study. As a result of the potential problems with
demonstration of light chains discussed above, one might
expect antibodies to light chains to demonstrate the poorest
concordance. This again was the case in the study, although the
sample size (n = 21) does not allow adequate confidence in the
magnitude of the difference between the two methods.
Even though the two methods were compared by using
antibodies directed against the same antigens, antibodies from
the same source were not used. Some difference in staining
between the two methods might therefore relate to differences
in the antibody specificities since these are monoclonal anti-
bodies. It is unlikely that this difference would be great enough
to prevent the observation of concordance as defined in the
present study. Because our goal was to compare FCM and
FSIP as they are routinely performed in skilled laboratories,
which carefully select and titrate antibodies specifically for
their respective methodologies, changes in the antibodies used
by each laboratory were not instituted for the present study.
FCM and FSIP were both able to assign a B- or a T-cell
lineage to the lymphomas. This does, however, raise a point
regarding the arbitrary assignment of markers to lymphocyte
subsets. In the present study, there were some apparent
discrepancies in "pan B-cell markers" within individual sam-
ples by FCM (Table 1). This may relate as much to the
heterogeneity of both tumors and benign lymphocyte subsets
as to the antibodies that were used and the markers that they
detected. In particular, CD20 as obtained in our laboratory is
not restricted to B cells but is present on a subset of T cells
which comprise on average 11% of the peripheral lymphocytes
in our healthy controls. Although most of the lymphoma
samples we presented had higher CD20 than CD19 values, the
differences often were small and could be attributed to CD20-
positive T cells.
Of foremost diagnostic importance in the immunophenotyp-
ing of lymph nodes is the demonstration of LCR in lymphomas
and the absence of LCR in benign lymph nodes. The first
obstacle in assessing LCR and comparing methods is one of
definition. LCR has been loosely described as a preponderance
of one light chain type, but the ability to quantify light-chain
expression by such methods as FCM has led investigators to
use various numerical definitions. These range from the most
liberal of a K/X ratio of .3.0 or .0.5 (27) to the most
conservative of a K/X ratio of .10 or <0.1 (21). Because benign
reactive lymphoid hyperplasias generally have k/X ratios in the
ranges of 0.3 to 1.0 and 3.0 to 7.0 (11, 14), we chose the criteria
for LCR = K/A > 7.5 or K/X < 0.25 in order to provide an
optimum separation of benign and malignant disorders while
maintaining a realistic uniform criterion for application to
FSIP as well as FCM. Because routine assessment of FSIP is
subjective, the definition of a "preponderance of one light
chain" is more widely used; however, we adopted a semiquan-
titative method of grading FSIP results to allow comparison
with the numeric data generated by FCM.
The second obstacle in comparing each method's ability to
demonstrate LCR is to establish a reference. For this purpose,
we arbitrarily assigned LCR to the B-cell lymphomas as
defined by morphology and surface immunoglobulin expres-
sion and its absence to all other samples. An alternate ap-
proach for comparing the methods would be to use molecular
studies for light-chain gene rearrangement as the reference.
Gene rearrangement analysis should be the most specific test
for demonstration of LCR and an ultimate gold standard for
comparing immunophenotyping methods. We did not perform
light-chain or T-cell receptor gene rearrangement analysis on
any of the study samples because this was beyond the scope of
our study and is not required for diagnosis. One would expect
molecular studies to confirm the theoretical assignment of
LCR to the B-cell lymphomas with surface immunoglobulins
and the lack thereof to the remaining samples. The only
predictable discrepancies would be those B-cell lymphomas
which fail to express surface immunoglobulins. There were no
such cases in the present study, although they reportedly make
up 12 to 15% of B-cell lymphomas and potentially hinder the
ability to demonstrate LCR by any method (11, 16).
Having thus compared the methods, the better sensitivity
and negative predictive value of FCM in the present study
likely relate to the problems in demonstrating surface immu-
noglobulins in tissue as described above, including the pres-
ence of polyclonal immunoglobulins in extracellular fluid and
connective tissue, variable immunoglobulin expression by lym-
phomas, and the difficulty in quantifying FSIP. In addition, the
small sample size precludes confidence in the magnitude of the
differences in diagnostic statistics between methods. Use of
image analysis to improve the quantification of FSIP might
improve the performance of FSIP.
Sampling error is another concern in studying lymph nodes.
FSIP requires the use of some portion of the total lymph node,
allowing the potential for sampling error in focal processes. No
sampling error in FSIP was encountered in the present study
on the basis of comparison of frozen sections with paraffin-
embedded sections. FCM requires preparation of a cell sus-
pension. Traditional methods include mechanical disaggrega-
tion of a portion of the total lymph node (35), which is subject
to the same potential for sampling error as FSIP. In addition,
the technique might introduce a selection bias if some cells are
more readily disaggregated than others. The ex vivo FNA
technique used in the present study had the potential benefit of
allowing sampling from all portions of the lymph node by
multiple redirected passes prior to sectioning. This likely would
decrease the potential for inadequate sampling of focal pro-
cesses; however, the possibility of selection bias would still
exist. On the basis of a comparison of smears of the aspirated
material, the FSIP and FCM results, and the paraffin-embed-
ded sections, appreciable sampling error was not experienced
with the FNA method in the present study.
In summary, FCM and FSIP are concordant methods for
immunophenotypic analysis of lymph node biopsies. FCM is
significantly more sensitive and has a significantly higher
negative predictive value for demonstration of LCR in lym-
phoid processes involving lymph nodes than FSIP. FCM and
FSIP can both identify characteristic immunophenotypes for
some T- and B-cell lymphomas. An ex vivo FNA technique is
a simple and reliable method for the collection of cell suspen-
sion samples of lymph node biopsies for FCM.
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